ISO 15378:2017 - Primary Packaging for Medicines Internal Auditor Free Practice Test — 30 Questions

Question 1

A pharmaceutical company receives notification from its primary glass vial supplier that a critical parameter in their glass melting process has been adjusted to improve energy efficiency. This adjustment, while not violating the supplier\'s own quality system, has the potential to subtly alter the chemical composition and surface properties of the glass. As an internal auditor for the pharmaceutical manufacturer, tasked with ensuring compliance with ISO 15378:2017, what is the most appropriate immediate action to recommend regarding the primary packaging material?

Accepted Answer

Initiate a re-validation process for the affected primary packaging material to confirm its continued suitability and performance.

Question 2

Consider a scenario where an internal audit of a pharmaceutical packaging manufacturer, adhering to ISO 15378:2017, uncovers that a key supplier of Type I borosilicate glass vials has reported a significant deviation in their furnace temperature control system, leading to a temporary alteration in the glass annealing process. This deviation could potentially affect the leachables profile of the vials. What is the most appropriate course of action for the organization\'s quality management system, as guided by the principles of ISO 15378:2017, to address this situation and ensure continued compliance and product integrity?

Accepted Answer

Initiate a formal change control process for the supplier's modified manufacturing method, conduct a comprehensive risk assessment of the potential impact on the primary packaging's leachables and extractables, and re-evaluate the supplier's qualification status based on the findings.

Question 3

During an internal audit of a pharmaceutical primary packaging manufacturer, a critical control point designed to prevent particulate contamination of sterile vials is found to be non-operational due to a calibration error. The risk assessment previously identified this specific contamination pathway as having a high potential impact and moderate likelihood. Which of the following actions represents the most appropriate immediate response from the internal auditor and the auditee, considering the principles of ISO 15378:2017 and effective risk management?

Accepted Answer

Initiate a root cause analysis for the control failure and implement immediate corrective actions to restore the control's functionality and effectiveness.

Question 4

During an audit of a pharmaceutical primary packaging manufacturer, it is discovered that a key supplier of sterile stoppers for a high-potency injectable drug product has reported a significant deviation in their sterilization validation process, potentially affecting a batch of stoppers already delivered. What is the primary focus of the internal auditor\'s investigation regarding this situation?

Accepted Answer

Verifying the effectiveness of the organization's incoming inspection and testing procedures for the delivered stoppers and reviewing the risk assessment for the supplier's critical processes.

Question 5

During an internal audit of a pharmaceutical company\'s primary packaging supplier management system, it is discovered that a critical supplier of sterile glass vials has recently implemented a new, validated terminal sterilization process. This change was communicated to the company, but no formal re-evaluation of the supplier\'s qualification status or the specific impact of the new sterilization method on the vial\'s leachables and extractables profile has been conducted. What is the most appropriate recommendation for the internal auditor to make regarding this situation, considering the requirements of ISO 15378:2017?

Accepted Answer

Recommend a formal re-assessment of the supplier's qualification, including a review of the new sterilization process's impact on material specifications and potential leachables/extractables.

Question 6

During an audit of a primary packaging material supplier for injectable medicines, an internal auditor reviews the supplier\'s quality management system. The supplier has provided documentation outlining their process for identifying and mitigating risks of microbial and particulate contamination. The auditor observes that the supplier\'s documented risk assessment procedure for raw material intake is comprehensive, detailing steps for supplier qualification and incoming material inspection. However, the auditor also notes that the supplier\'s manufacturing area has a history of minor environmental control deviations, which are addressed through corrective actions but are not explicitly linked back to a formal re-evaluation of the risk assessment for the finished primary packaging components. Which of the following audit findings most accurately reflects a potential non-conformity related to the supplier\'s risk management process as per ISO 15378:2017?

Accepted Answer

The supplier's documented risk assessment process for contamination does not adequately demonstrate the integration of environmental control deviations into the ongoing evaluation of risks associated with primary packaging materials.

Question 7

When auditing a critical process for the manufacture of primary pharmaceutical packaging, what is the most comprehensive method for an internal auditor to verify that the implemented controls are effectively preventing deviations and ensuring product quality, as required by ISO 15378:2017?

Accepted Answer

Conducting a thorough review of all documented procedures, validation reports, and training records related to the process, followed by direct observation of the process in operation and interviews with key personnel involved in its execution.

Question 8

During an internal audit of a pharmaceutical company manufacturing sterile injectables, an auditor identifies a critical risk associated with a new supplier of elastomeric stoppers. The risk assessment indicates a potential for sub-visible particulate contamination exceeding acceptable limits, which could compromise product sterility and patient safety. The supplier has provided documentation outlining enhanced cleaning protocols and in-process particle monitoring for the stopper manufacturing process. What is the most crucial aspect the auditor must verify to ensure compliance with ISO 15378:2017 and relevant GMP principles regarding this identified risk?

Accepted Answer

Evidence of a validated process demonstrating the consistent effectiveness of the supplier's mitigation strategies for particulate contamination.

Question 9

When conducting an internal audit of a primary packaging manufacturer\'s compliance with ISO 15378:2017, what aspect of the supplier management system provides the most robust evidence that the organization is proactively mitigating the risk of receiving non-conforming materials?

Accepted Answer

The documented process for evaluating, selecting, and monitoring external providers, with a clear linkage between identified supplier-specific risks and the controls implemented during their qualification and ongoing performance assessment.

Question 10

During an internal audit of a primary packaging manufacturer for pharmaceutical products, an auditor observes that while environmental monitoring data for particulate matter in the cleanroom is collected, the documented procedure for actioning results exceeding the defined alert limits lacks specific timelines and clear responsibilities for initiating investigations and implementing corrective actions. This observation raises concerns regarding the proactive management of potential contamination risks. What is the most appropriate auditor action to address this finding in accordance with ISO 15378:2017 principles?

Accepted Answer

Document the observation as a non-conformity and recommend a review of the procedure to establish clear timelines, responsibilities, and escalation pathways for addressing environmental monitoring deviations.

Question 11

During an internal audit of a pharmaceutical primary packaging manufacturer, a significant finding of foreign particulate matter was identified in a batch of sterile vials. The quality assurance team has documented corrective actions taken, including enhanced cleaning protocols and a change in raw material supplier. What is the most critical subsequent step an internal auditor should verify to ensure the effectiveness of the quality management system in addressing this nonconformity according to ISO 15378:2017?

Accepted Answer

Confirmation that the implemented corrective actions have been verified for their effectiveness in preventing the recurrence of particulate contamination.

Question 12

During an internal audit of a pharmaceutical packaging manufacturer adhering to ISO 15378:2017, it was discovered that a batch of critical primary packaging components, specifically sterile stoppers for injectable medications, failed to meet a key dimensional tolerance during incoming inspection. The non-conformance was identified through routine testing. Which of the following actions best reflects the auditor\'s recommendation to ensure ongoing compliance and mitigate future risks associated with this supplier and component?

Accepted Answer

Initiate a comprehensive re-evaluation of the supplier's qualification status and the effectiveness of quality controls for this critical component.

Question 13

During an audit of a primary packaging material supplier for sterile injectables, it was discovered that the manufacturer of specialized borosilicate glass vials had recently implemented a 15°C increase in their glass annealing temperature to improve production efficiency. This change was documented internally but lacked any subsequent re-validation of the glass\'s chemical resistance properties or its leachables profile against the intended drug product. What is the most critical finding for an internal auditor to report concerning ISO 15378:2017 compliance?

Accepted Answer

The supplier failed to conduct and document appropriate validation activities following a significant process change that could impact the quality and safety of the primary packaging.

Question 14

During an internal audit of a pharmaceutical company\'s primary packaging material qualification process, an auditor is reviewing the introduction of a novel polymer film for blister packs. The risk assessment identified potential migration of specific additives from the film into the drug product. The company has implemented supplier-specific quality agreements and established in-process testing for incoming film batches. At what point in the lifecycle of this new material should the auditor verify that the implemented controls are effectively mitigating the identified migration risks?

Accepted Answer

During the validation of the material's performance in the final packaged product under simulated storage conditions.

Question 15

During an audit of a pharmaceutical company\'s primary packaging supplier qualification process, an auditor discovers that a supplier of sterile glass vials, previously validated for dimensional stability and particulate matter, has proposed a minor, documented adjustment to their glass melting temperature. The supplier has provided an internal risk assessment concluding the change is inconsequential to vial integrity. What is the auditor\'s primary responsibility in evaluating the company\'s acceptance of this proposed supplier process modification?

Accepted Answer

Verify that the company's quality unit has independently reviewed and concurred with the supplier's risk assessment, ensuring the rationale for accepting the deviation is scientifically sound and documented.

Question 16

Consider a scenario where an internal audit of a pharmaceutical primary packaging manufacturer reveals that a key supplier of sterile stoppers experienced a documented microbial contamination event in their production facility six months prior. Although the supplier provided a corrective action report detailing remediation efforts and claimed the issue was resolved, the packaging manufacturer has not formally updated its supplier risk assessment for this critical raw material or implemented any enhanced incoming testing protocols for subsequent batches. As an internal auditor, what is the most appropriate verification step to assess the effectiveness of the manufacturer\'s risk management process in this context?

Accepted Answer

Confirm that the packaging manufacturer has initiated a formal re-evaluation of the supplier's risk profile and the suitability of the affected raw material, including potential changes to incoming testing procedures.

Question 17

During an audit of a primary packaging material supplier for sterile injectable medications, an internal auditor is reviewing the supplier\'s risk management process for a critical raw material. The supplier has identified a significant risk of microbial contamination during the material\'s synthesis and subsequent handling. What specific aspect of the supplier\'s risk management documentation should the auditor prioritize for verification to ensure the effectiveness of their controls?

Accepted Answer

Verification of the supplier's documented procedures for environmental monitoring of production areas and validation of cleaning processes for equipment used in the raw material's synthesis.

Question 18

Following the identification of a critical non-conformity during an internal audit concerning particulate contamination in sterile glass vials, what is the primary objective of the auditor\'s follow-up verification of the implemented corrective and preventive actions (CAPA)?

Accepted Answer

To confirm that the root cause analysis was thorough and that the implemented corrective actions have effectively eliminated the recurrence of the non-conformity and that preventive measures are in place.

Question 19

When conducting an internal audit of a primary packaging manufacturer for medicinal products, what is the most effective approach for an auditor to ascertain the overall effectiveness of the organization\'s Quality Management System (QMS) in relation to ISO 15378:2017 requirements?

Accepted Answer

Evaluating the documented procedures and their consistent application across all operational stages, from raw material receipt to final product dispatch, to ensure alignment with the standard and organizational objectives.

Question 20

During an internal audit of a pharmaceutical company\'s primary packaging material control system, an auditor reviews the risk assessment for a newly qualified supplier of Type I borosilicate glass vials. The risk assessment identified a critical control point related to the annealing process, which is crucial for preventing thermal shock and ensuring container integrity. However, the auditor discovers that while this control point was documented in the risk assessment and included in the supplier\'s manufacturing process flow, no specific validation study was conducted or referenced to confirm the effectiveness of the annealing process parameters prior to the release of the first commercial batch of vials. Which of the following represents the most appropriate auditor finding and recommended action according to the principles of ISO 15378:2017?

Accepted Answer

Identify a non-conformity due to the lack of documented validation for a critical control point, recommending the implementation of a validation study to confirm the annealing process effectiveness.

Question 21

An internal audit of a pharmaceutical primary packaging manufacturer reveals that a long-standing supplier of a critical polymer film for blister packs has been providing material with a minor, undocumented alteration in its chemical composition. This alteration was identified during routine incoming material inspection but was not formally reported or assessed by the quality unit. The supplier claims the change is insignificant and does not affect performance. What is the most significant non-conformance with ISO 15378:2017 identified in this scenario?

Accepted Answer

Failure to conduct a formal risk assessment and implement a management of change process for the supplier's material deviation.

Question 22

During an internal audit of a pharmaceutical primary packaging manufacturer, an auditor is reviewing the effectiveness of the Quality Management System. The organization produces sterile glass vials for injectable medicines. Which of the following areas of focus for the auditor would most directly demonstrate compliance with the overarching regulatory framework governing pharmaceutical packaging, as implicitly required by ISO 15378:2017?

Accepted Answer

Verification of the manufacturer's adherence to Good Manufacturing Practices (GMP) principles relevant to sterile product packaging.

Question 23

During an internal audit of a pharmaceutical company manufacturing sterile injectables, it is discovered that a key supplier of critical primary packaging components, specifically silicone stoppers for vials, has reported a significant batch failure due to unacceptable levels of extractables. The company\'s quality management system, aligned with ISO 15378:2017, mandates a risk-based approach to supplier management. What is the most appropriate immediate action for the internal auditor to verify concerning the company\'s response to this supplier issue?

Accepted Answer

Confirm that the company has initiated a comprehensive investigation into the supplier's non-conformity, including an assessment of the root cause, a review of the impact on previously released product, and the implementation of enhanced controls for future incoming batches.

Question 24

During an audit of a primary packaging material supplier for sterile pharmaceutical products, an internal auditor is reviewing the supplier\'s quality management system. The auditor needs to assess the supplier\'s proactive measures to prevent cross-contamination of glass vials intended for parenteral administration. Which of the following actions by the auditor would most effectively demonstrate the supplier\'s adherence to ISO 15378:2017 requirements for controlling contamination risks?

Accepted Answer

Reviewing the supplier's documented procedures for environmental monitoring and particulate control within their glass vial manufacturing cleanroom, and verifying records of recent monitoring results against established acceptance criteria.

Question 25

During an audit of a primary packaging material supplier for sterile injectable pharmaceuticals, an auditor is reviewing the supplier\'s process for managing risks associated with potential microbial contamination of critical components. The supplier manufactures sterile glass vials intended for a new biologic drug product. What is the most appropriate action for the auditor to take to verify the effectiveness of the supplier\'s risk management for this specific concern?

Accepted Answer

Review the supplier's documented risk management process and evidence of its application to the sterile glass vial production, focusing on identified microbial contamination risks and implemented controls.

Question 26

During an audit of a pharmaceutical company\'s primary packaging supplier, an auditor discovers that the supplier has unilaterally implemented a minor modification to the curing process for a critical elastomer used in vial stoppers. The supplier provided a new certificate of analysis for the modified elastomer, stating it meets all specified chemical and physical properties. The pharmaceutical company\'s quality agreement with the supplier requires notification and approval for any process changes that could potentially impact product quality. What is the most significant internal audit finding concerning the supplier\'s adherence to ISO 15378:2017 and associated pharmaceutical quality expectations?

Accepted Answer

Failure to conduct a comprehensive risk assessment and obtain prior approval from the pharmaceutical manufacturer for a process change impacting a critical component.

Question 27

When auditing a potential new supplier for sterile glass vials intended for parenteral drug products, an internal auditor discovers that the supplier\'s proposed manufacturing process for vial coating has not undergone a formal risk assessment concerning potential leachables and extractables. The supplier has provided a basic certificate of analysis for the coating material but has not detailed the validation of their coating process or its impact on drug product stability. Considering the stringent requirements of ISO 15378:2017 and relevant pharmaceutical regulations, what is the most critical immediate action the auditor should recommend to the organization before approving this supplier for the critical vial component?

Accepted Answer

Mandate a comprehensive on-site audit of the supplier's manufacturing processes, quality management system, and validation documentation specifically focusing on the coating application and its potential impact on leachables and extractables.

Question 28

During an internal audit of a primary packaging manufacturer for sterile pharmaceutical products, a finding is raised concerning the inconsistent monitoring of a critical process parameter for elastomeric vial stoppers. Specifically, records indicate that the melt flow index of the polymer, a key characteristic influencing seal integrity and extractables, was not recorded for several batches within the specified tolerance. What is the most appropriate next step for the internal auditor to take in addressing this non-conformity according to the principles of ISO 15378:2017?

Accepted Answer

Investigate the potential impact of the parameter variability on stopper performance and verify the effectiveness of existing controls in preventing such deviations.

Question 29

During an internal audit of a primary packaging manufacturer for medicinal products, a significant non-conformity was raised concerning particulate contamination exceeding acceptable limits in a batch of Type I borosilicate glass vials. The quality department subsequently implemented corrective actions, including enhanced environmental monitoring in the cleanroom, revised cleaning procedures for the vial handling equipment, and additional training for personnel involved in the packaging process. As the internal auditor, what is the most appropriate next step to ensure the effectiveness of these corrective actions?

Accepted Answer

Conduct follow-up verification activities to confirm the sustained effectiveness of the implemented corrective actions and the absence of recurrence.

Question 30

During an internal audit of a pharmaceutical packaging facility adhering to ISO 15378:2017, an auditor discovers that a new supplier for primary glass vials, identified as having a high-risk profile due to their recent implementation of a novel manufacturing process, has been approved and is currently supplying materials. However, the audit trail indicates that no formal validation study was conducted to confirm the suitability and consistent performance of these vials under the facility\'s specific processing conditions and in contact with the intended medicinal product, prior to their routine use. Which of the following audit findings most accurately reflects a potential non-conformity with the standard\'s requirements for managing supplier changes and ensuring product quality?

Accepted Answer

The audit finding should focus on the lack of a documented validation study to confirm the suitability of the new supplier's glass vials for their intended use, given the identified high-risk profile of the supplier.

ISO 15378:2017 - Primary Packaging for Medicines Internal Auditor Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 15378:2017 - Primary Packaging for Medicines Internal Auditor Certification